ストックスクリーナーアプリを入手
8.165
0.81%
-0.075
アフターアワーズ：
8.15
-0.015
-0.18%
前日終値:
$8.24
開ける：
$8.22
24時間の取引高:
2.10M
Relative Volume:
0.30
時価総額：
$1.89B
収益：
$510.17M
当期純損益:
$146.93M
株価収益率:
13.63
EPS:
0.599
ネットキャッシュフロー:
$27.51M
1週間 パフォーマンス:
-5.30%
1か月 パフォーマンス:
-27.42%
6か月 パフォーマンス:
-57.30%
1年 パフォーマンス:
-59.98%
1日の値動き範囲:
$8.08
$8.285
1週間の範囲:
$8.08
$8.78
52週間の値動き範囲:
$7.2101
$22.37
Adma Biologics Inc Stock (ADMA) Company Profile
Compare ADMA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
8.14 | 1.91B | 510.17M | 146.93M | 27.51M | 0.599 |
VRTX
Vertex Pharmaceuticals Inc
|
436.05 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.30 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-21 | 開始されました | Canaccord Genuity | Buy |
| 2026-03-26 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-07-19 | 再開されました | Raymond James | Strong Buy |
| 2022-10-13 | 開始されました | Mizuho | Buy |
| 2021-11-11 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-06-04 | 開始されました | Jefferies | Buy |
| 2019-04-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-07 | 再開されました | H.C. Wainwright | Buy |
| 2017-12-11 | 繰り返されました | Maxim Group | Buy |
| 2017-11-14 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | アップグレード | Maxim Group | Hold → Buy |
| 2016-08-01 | ダウングレード | Maxim Group | Buy → Hold |
| 2016-07-25 | 繰り返されました | Maxim Group | Buy |
| 2015-05-13 | 繰り返されました | Maxim Group | Buy |
| 2014-12-08 | 開始されました | Oppenheimer | Outperform |
| 2014-12-01 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Adma Biologics Inc (ADMA) 最新ニュース
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are ... - Caledonian Record
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
$ADMA Shareholder Announcement: ADMA Biologics may have - GlobeNewswire
ADMA Biologics Inc (ADMA) Stock Analysis: Exploring a 103% Potential Upside with Robust Revenue Growth - DirectorsTalk Interviews
ADMA Biologics declines 17% after lowering FY26 outlook, withdrawing long-term guidance - MSN
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action InvestigationADMA - PR Newswire
IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
Lowey Dannenberg, P.C. is Investigating ADMA Biologics - GlobeNewswire
Will the IG Market Challenges Affect ADMA Biologics Prospects in 2026? - Zacks Investment Research
B Group Increases Stake in ADMA Biologics by 750,000 Shares - Intellectia AI
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year - The Motley Fool
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc.ADMA - PR Newswire
A Look At ADMA Biologics (ADMA) Valuation After Securities Fraud Probes And Guidance Withdrawal - Sahm
ADMA Securities Investigation: ADMA Biologics 29% Stock - GlobeNewswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc.ADMA - FinancialContent
Why are shares of ADMA Biologics falling today? - MSN
Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge? - TradingView
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inqu - GuruFocus
ADMA Biologics Inc (ADMA) Stock Price, Trades & News - GuruFocus
ADMA Fraud Notice: ADMA Biologics is being Investigated for - GlobeNewswire
ADMA Biologics Inc (ADMA) Stock Analysis: A Biotech With 102.54% Potential Upside - DirectorsTalk Interviews
Understanding the Setup: (ADMA) and Scalable Risk - Stock Traders Daily
Thrivent Financial for Lutherans Cuts Position in ADMA Biologics Inc $ADMA - MarketBeat
How Channel Stuffing Probes and ASCENIV’s Pediatric Expansion Will Impact ADMA Biologics (ADMA) Investors - Yahoo Finance
ADMA Biologics (ADMA) price target decreased by 26.10% to 17.08 - MSN
ADMA Shareholder News: ADMA Biologics Investigated for Securities Fraud Over Alleged Misrepresentations about Channel Stuffing – Investors Notified to Contact BFA Law - GlobeNewswire
ADMA Biologics IncCommon Stock (NQ: ADMA - FinancialContent
Here’s What Analysts Think About ADMA Biologics (ADMA) - Insider Monkey
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Adma biologics director Jerrold Grossman buys $100,125 in stock By Investing.com - Investing.com Nigeria
Adma biologics director Jerrold Grossman buys $100,125 in stock - Investing.com
ADMA Biologics (NASDAQ: ADMA) director adds 12,500 shares in open-market buy - Stock Titan
A Look At ADMA Biologics (ADMA) Valuation After Short Seller Allegations And Legal Investigations - Sahm
New Strong Sell Stocks for May 14th - The Globe and Mail
ADMA Investor News: If You Have Suffered Losses in ADMA - GlobeNewswire
ADMA Biologics Fair Value call delivered 50% gain despite volatility By Investing.com - Investing.com India
ADMA Biologics Fair Value call delivered 50% gain despite volatility - Investing.com UK
Adma Biologics director buys $100,125 of common stock - Investing.com UK
Adma Biologics director buys $100,125 of common stock By Investing.com - Investing.com Nigeria
Adma Biologics Inc (ADMA) 財務データ
収益
当期純利益
現金流量
EPS
Adma Biologics Inc (ADMA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Grossman Jerrold B | Director |
May 11 '26 |
Buy |
8.01 |
12,500 |
100,125 |
501,384 |
| Guiheen Lawrence P. | Director |
Mar 13 '26 |
Option Exercise |
3.66 |
30,000 |
109,800 |
135,520 |
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Option Exercise |
5.40 |
15,000 |
81,000 |
2,133,777 |
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Sale |
15.16 |
21,000 |
318,360 |
2,112,777 |
2.25%
0.46%
大文字化:
|
ボリューム (24 時間):